Clinical value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy.

Metastatic Breast ◽

First Line ◽

Clinical Value ◽

Epithelial Tumor ◽

First Line Therapy ◽

Abstract P3-02-11: First Analysis of the Value of Circulating Epithelial Tumor Cells and Circulating Endothelial Cells (CTCs/CECs) in Patients with HER-2 Negative Recurrent or Metastatic Breast Cancer Treated with Bevacizumab in Combination with Paclitaxel and Gemcitabine as First Line Therapy (AVALUZ Trial)

10.1158/0008-5472.sabcs10-p3-02-11 ◽

2010 ◽

Author(s):

L Manso ◽

E Ciruelos ◽

M Codes de Villena ◽

J de la Haba ◽

A Galán ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Metastatic Breast ◽

First Line ◽

Epithelial Tumor ◽

First Line Therapy ◽

Line Therapy ◽

Her 2

Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy

Breast Cancer Research ◽

10.1186/bcr3025 ◽

2011 ◽

Vol 13 (S2) ◽

Author(s):

L Manso ◽

E Ciruelos ◽

M Codes ◽

J De la Haba ◽

A Galan ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Prognostic Value ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

High Level

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdq052 ◽

2010 ◽

Vol 21 (9) ◽

pp. 1765-1771 ◽

Cited By ~ 104

Author(s):

F.-C. Bidard ◽

C. Mathiot ◽

A. Degeorges ◽

M.-C. Etienne-Grimaldi ◽

R. Delva ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Cancer Patients ◽

Tumor Cells ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

Clinical Value

WITHDRAWN: Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group

The Breast ◽

10.1054/brst.2002.0469 ◽

2002 ◽

Author(s):

B. Ejlertsen ◽

I. Højris ◽

S. Hansen ◽

K. Møholt ◽

B. Kristensen ◽

...

Keyword(s):

Breast Cancer ◽

Pilot Study ◽

Metastatic Breast ◽

Cooperative Group ◽

First Line ◽

First Line Therapy ◽

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603351 ◽

2006 ◽

Vol 95 (7) ◽

pp. 788-793 ◽

Cited By ~ 43

Author(s):

A Chan ◽

◽

M Martin ◽

M Untch ◽

M G Gil ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Her 2

Phase II Trial of Weekly Vinorelbine and Trastuzumab as First‐Line Therapy in Patients with HER2 + Metastatic Breast Cancer

The Oncologist ◽

10.1634/theoncologist.7-5-410 ◽

2002 ◽

Vol 7 (5) ◽

pp. 410-417 ◽

Cited By ~ 107

Author(s):

Mohammad Jahanzeb ◽

Joanne E. Mortimer ◽

Furhan Yunus ◽

David H. Irwin ◽

James Speyer ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

10.1055/s-0041-1730221 ◽

2021 ◽

Author(s):

A Schneeweiss ◽

D Miles ◽

E Ciruelos ◽

F Puglisi ◽

T Peretz-Yablonski ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy ◽

Global Study ◽

Locally Recurrent

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan

Anti-Cancer Drugs ◽

10.1097/cad.0b013e328302eb15 ◽

2008 ◽

Vol 19 (7) ◽

pp. 753-759 ◽

Cited By ~ 8

Author(s):

Nahomi Tokudome ◽

Yoshinori Ito ◽

Kiyohiko Hatake ◽

Masakazu Toi ◽

Muneaki Sano ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Pharmacokinetic Study ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).

10.1158/0008-5472.sabcs-09-44 ◽

2009 ◽

Cited By ~ 23

Author(s):

W. Gradishar ◽

V. Kaklamani ◽

T. Prasad Sahoo ◽

D. Lokanatha ◽

V. Raina ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent

Superiority of Docetaxel + Capecitabine Compared to Docetaxel + Epirubicin as First-Line Therapy for Metastatic Breast Cancer – Final Results of the ERASME-4 Study.

10.1158/0008-5472.sabcs-09-2099 ◽

2009 ◽

Author(s):

T. Bachelot ◽

A. Bajard ◽

I. Ray-Coquard ◽

J. Provencal ◽

D. Coeffic ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽